ProjectMJFF 025709 PNPO – Dried Blood spot PNPO activity as a biomarker for the stratification of Parkinson's Disease
Basic data
Acronym:
MJFF 025709 PNPO
Title:
Dried Blood spot PNPO activity as a biomarker for the stratification of Parkinson's Disease
Duration:
01/05/2025 to 30/04/2027
Abstract / short description:
Biomarkers that reflect the main biological features of Parkinson’s disease (PD) such as mitochondrial damage, lysosomal dysfunction, protein homeostasis/alpha-synuclein, and inflammation enable the stratification of PD and precision medicine. However, there is a pressing need for predictive blood biomarkers. Our research has demonstrated that a subset of PD patients exhibits lower levels of pyridox(am)ine 5’-phosphate oxidase (PNPO) enzyme activity levels in dried blood spots compared to the control range. PNPO is a key enzyme involved in the synthesis of the active form of vitamin B6 that is essential for mitochondrial function, neurotransmitter synthesis and anti-inflammatory responses.
Involved staff
Managers
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Other staff
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Hertie Institute for Clinical Brain Research (HIH)
Non-clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
New York, United States
Cooperations
London, United Kingdom
Pavia, Lombardei, Italy